TY  - JOUR
TI  - The Role of 18F-FLT PET/CT in Assessing Early Response to  Transarterial Radioembolization and Chemoembolization in  Patients with Primary and Metastatic Liver Tumors
AB  - Objectives: Metastases and primary malignancies are common in the liver. Local ablative applications such as transarterial chemoembolization  (TACE), and transarterial radioembolization (TARE) provide minimally invasive and safe treatment in unresectable liver tumors. Early detection  of response to treatment prevents unnecessary toxicity and cost in non-responder patients and provides an earlier use of other options that  may be effective. This study aimed to identify the role of 18F-fluorothymidine (FLT) positron emission tomography/computed tomography  (PET/CT) in the assessment of early response to TACE and TARE treatments in patients with unresectable primary and metastatic liver tumors. Methods: This single-center study included 63 patients who underwent 18F-FLT PET/CT for response evaluation after TACE and TARE. After excluding  20 patients whose data were missing 43 TARE-receiving patients were analyzed. The compatibility of change in semi-quantitative values obtained from  the 18F-FLT PET/CT images with the treatment responses detected in 18F-fluorodeoxyglucose PET/CT, CT, and MR images and survival was evaluated. Results: There was no correlation between early metabolic, morphological response, and 18F-FLT uptake pattern, and change  in standardized uptake values (SUV) which were ΔSUVmax, ΔSUVmean, ΔSUVpeak., ΔSUVmean, ΔSUVpeak values. There was no  significant correlation between 18F-FLT uptake pattern, ΔSUVmax, ΔSUVmean, ΔSUVpeak, and overall survival, progression-free survival  (PFS) for the target lobe PFS for the whole-body. The survival distributions for the patients with >30% change in ΔSUVmax and  ΔSUVpeak values were statistically significantly longer than the patients with <30% change (p<0.009 and p<0.024, respectively). Conclusion: There was significant longer PFS for target liver lobe in patients with more than 30% decrease in 18F-FLT SUVmax and SUVpeak of the  liver lesion in primary and metastatic unresectable liver tumors undergoing TARE.
AU  - kucuk, nuriye ozlem
AU  - Kır, Kemal Metin
AU  - bilgic, sadık
AU  - NAK, DEMET
AU  - Hayme, Serhat
AU  - Celebioglu, Emre Can
DO  - 10.4274/mirt.galenos.2022.85579
PY  - 2022
JO  - Molecular Imaging and Radionuclide Therapy
VL  - 31
IS  - 3
SN  - 2146-1414
SP  - 207
EP  - 215
DB  - TRDizin
UR  - http://search/yayin/detay/1137084
ER  -